Enveric Biosciences, Inc.
ENVB
$1.41
$0.08086.08%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 6.05M | 6.08M | 6.60M | 5.06M | 5.90M |
| Depreciation & Amortization | 288.30K | 333.10K | 337.50K | 339.70K | 341.20K |
| Other Operating Expenses | -246.10K | -246.10K | -246.10K | -107.20K | -107.20K |
| Total Operating Expenses | 9.96M | 9.34M | 9.63M | 8.84M | 10.21M |
| Operating Income | -9.96M | -9.34M | -9.63M | -8.84M | -10.21M |
| Income Before Tax | -9.94M | -9.30M | -9.57M | -9.83M | -10.56M |
| Income Tax Expenses | 7.20K | 7.20K | 8.90K | 24.00K | 30.60K |
| Earnings from Continuing Operations | -9.94 | -9.30 | -9.57 | -9.86 | -10.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -9.94M | -9.30M | -9.57M | -9.86M | -10.59M |
| EBIT | -9.96M | -9.34M | -9.63M | -8.84M | -10.21M |
| EBITDA | -9.68M | -9.01M | -9.29M | -8.50M | -9.87M |
| EPS Basic | -10.58 | -13.32 | -21.32 | -39.07 | -55.04 |
| Normalized Basic EPS | -6.60 | -8.32 | -13.31 | -24.33 | -34.28 |
| EPS Diluted | -10.58 | -13.32 | -21.32 | -39.07 | -55.04 |
| Normalized Diluted EPS | -6.60 | -8.32 | -13.31 | -24.33 | -34.28 |
| Average Basic Shares Outstanding | 5.63M | 3.54M | 2.01M | 1.51M | 1.07M |
| Average Diluted Shares Outstanding | 5.63M | 3.54M | 2.01M | 1.51M | 1.07M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |